"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

and Taltz and Olumiant for immunology. Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance. Where Is Eli Lilly ...

Eli Lilly is one of the front runners in the bid ... The new immunology unit meanwhile will centre around psoriasis therapy Taltz (ixekizumab), which grew 44% to almost $570 million in the second ...

Eli Lilly has struck a $2.4 billion deal to buy ... like Novartis’ multibillion-dollar blockbuster Cosentyx (secukinumab), Lilly’s Taltz (ixekizumab), Bausch Health/Ortho’s Siliq (brodalumab ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.